Results 81 to 90 of about 75,591 (303)

Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder

Addiction Science & Clinical Practice
Background Medications for opioid use disorder (MOUD) are among the best tools available to combat the opioid epidemic. Yet, use of MOUD among people with opioid use disorder (OUD) remains low.
Nicholas C. Cardamone, Rebecca E. Stewart, Kyle M. Kampman, Steven C. Marcus   +3 more
doaj   +1 more source

Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle‐Aquitaine

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The French authorities mandated the use of secure prescriptions for pregabalin on May 2021. This study aimed to evaluate the impact of this measure on pregabalin use and misuse in Nouvelle‐Aquitaine, a southwestern French region with around six million inhabitants.
Maika Munech‐Herran, Véronique Moysan, Bruno Lescarret, Clément Mathieu, Antoine Pariente, Nicolas Rousselot   +5 more
wiley   +1 more source

Incarceration history and opioid use among adults living with HIV and chronic pain: a secondary analysis of a prospective cohort study

Health & Justice
Background Adults living with HIV have disproportionately high chronic pain, prescription opioid use, history of substance use, and incarceration. While incarceration can have long-lasting health impacts, prior studies have not examined whether distant (>
Anna B. Lichtiger, Yuting Deng, Chenshu Zhang, Justina Groeger, Hector R. Perez, Gayatri Nangia, Melanie Prinz, Emma Richard, Matthew Glenn, Ana Alicia De La Cruz, Ariana Pazmino, Chinazo O. Cunningham, K Rivet Amico, Aaron Fox, Joanna L. Starrels   +14 more
doaj   +1 more source

Impact of continuing care on recovery from substance use disorder.

, 2021
Continuing care is widely believed to be an important component of effective treatment for substance use disorder, particularly for those individuals with greater problem severity.
McKay, James R
core   +1 more source

Editorial: Opioids and opioid-use disorders

Frontiers in Pharmacology, 2023
Giordano de Guglielmo, Marsida Kallupi, Andrea Cippitelli, Daniele Caprioli, Daniele Caprioli, Kabirullah Lutfy   +5 more
openaire   +4 more sources

Effect of oxycodone vs. morphine as first‐line opioid on new persistent opioid use after orthopaedic surgery: A prospective sequential cohort study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background Postoperative opioids, intended for short‐term analgesia, contribute to new persistent opioid use in 1%–7% of patients, adversely affecting outcomes. Oxycodone may carry higher risk than morphine, though long‐term data are limited.
Eward J. Melis, Johanna E. Vriezekolk, Frédérique H. C. Bollen, Dirk E. Schrander, Arnt F. A. Schellekens, Bart J. F. van den Bemt   +5 more
wiley   +1 more source

Patients with opioid use disorder choosing treatment with extended-release naltrexone: a 6-month naturalistic study.

INTRODUCTION: The treatment efficacy of extended-release naltrexone (XR-NTX) for opioid use disorder (OUD) has been demonstrated in several studies, but not in naturalistic settings where opioid agonist treatment (OAT) is freely accessible.
Tanum, Lars, Mordal, Jon, Løberg, Else-Marie, Solli, Kristin K, Waleur, Karin Merethe, Brenna, Ida Halvorsen, Weimand, Bente, Benth, Jūratė Šaltytė   +7 more
core   +1 more source

Non-pharmacologic interventions for opioid use disorder

, 2021
Peer-reviewed publications - scoping review of non-pharmacologic interventions for opioid use disorder ...
Wild, Cam
core   +1 more source

Psychotropic medication use among community dwellers with and without Parkinson's disease – A nationwide cohort study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims We studied the prevalence of psychotropic use and psychotropic polypharmacy in persons with Parkinson's disease (PD) during a 10‐year follow‐up, because longitudinal studies on this topic are scarce although non‐motor symptoms of PD are often treated with psychotropics.
Noora Nieminen, Anna‐Maija Tolppanen, Valtteri Kaasinen, Marjaana Koponen, Sirpa Hartikainen   +4 more
wiley   +1 more source

Increasing the reporting of adverse drug reaction‐related hospitalizations using an ICD‐10‐based identification workflow: A multicentre study from Switzerland

British Journal of Clinical Pharmacology, EarlyView.
Background Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under‐reporting remains widespread. We tested a novel method to increase reporting of ADR‐related hospitalizations.
Georgia Anita Weber, Sophie‐Charlotte Bartel, Michael Boch, Christoph Rosen, Michael Bodmer, Balthasar Luzius Hug, Thomas Stammschulte, Patrick E. Beeler   +7 more
wiley   +1 more source